Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing disorders, today announced that its investigational drug GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.

View article:
Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Scroll to Top